Sandbox Reserved 914
From Proteopedia
(Difference between revisions)
(2 intermediate revisions not shown.) | |||
Line 7: | Line 7: | ||
[[Image:pymol.png|300px|left|thumb|'''Figure 1:'''Three dimensional structure of Palmitoyl-Protein Thioesterase 1. The blue color represents the α-helices and the purple represents the β-sheets. The pink signifies random coil.]] | [[Image:pymol.png|300px|left|thumb|'''Figure 1:'''Three dimensional structure of Palmitoyl-Protein Thioesterase 1. The blue color represents the α-helices and the purple represents the β-sheets. The pink signifies random coil.]] | ||
- | Palmitoyl-Protein Thioesterase 1 (PPT1) is a lysosomal enzyme that plays a role in the degradation of lipid-modified proteins<ref name="human">Palmitoyl | + | Palmitoyl-Protein Thioesterase 1 (PPT1) is a lysosomal enzyme that plays a role in the degradation of lipid-modified proteins<ref name="human">"Palmitoyl Protein Thioesterase 1." UniProt. N.p., 1 Oct. 1996. Web. 10 Apr. 2014.</ref>. PPT1 derives its catalytic power from its [http://en.wikipedia.org/wiki/Catalytic_triad catalytic triad], [http://en.wikipedia.org/wiki/Alpha/beta_hydrolase_fold α/β hydrolase fold], and hydrophobic groove in order to remove fatty acid acyl groups, typically [http://en.wikipedia.org/wiki/Palmitic_acid palmitate] from cysteine residues in proteins<ref name="human"/>. PPT1 is able to be modified by cofactor enzymes, which can induce biological changes<ref name="human"/>. Misregulation of PPT1 modifications can cause various diseases, including infantile neuronal ceroid lipofuscinosis<ref name="PPT"/>, kufs disease<ref name="PPT"/>, and late-infantile neuronal ceroid lipofuscinosis<ref name="PPT"/>. Within these diseases, the production of PPT1 is decreased or eliminated completely, which leads to fatty acid buildup primarily in neuronal cells, leading to slowed developmental progress<ref name="PPT"/>. |
Line 16: | Line 16: | ||
=== Catalytic Triad === | === Catalytic Triad === | ||
- | The <scene name='57/573128/2/1'>catalytic triad</scene> is composed of Ser115, His289, and Asp233, which is the same as the catalytic triad in [http://en.wikipedia.org/wiki/Chymotrypsin chymotrypsin] <ref name="human"/>. A water molecule is occupying the <scene name='57/573128/7/1'>oxyanion hole</scene> and it is hydrogen bonded to Ser115 <ref name="Prom"/>. The purpose of the oxyanion hole is to stabilize the oxyanion that is formed after the nucleophilic attack of the transition state. Ser115 acts as a nucleophile, while His289 and Asp233 are coordinated to Ser115 to lower its pKa value so it can undergo catalytic activity<ref name="Prom"/>. The pKa of the nucleophile in the catalytic triad is lowered to allow the nucleophilic attack<ref name="Prom">Branneby, Cecilia. Exploiting Enzyme Promiscuity for Rational Design. KTH Biotechnology. | + | The <scene name='57/573128/2/1'>catalytic triad</scene> is composed of Ser115, His289, and Asp233, which is the same as the catalytic triad in [http://en.wikipedia.org/wiki/Chymotrypsin chymotrypsin] <ref name="human"/>. A water molecule is occupying the <scene name='57/573128/7/1'>oxyanion hole</scene> and it is hydrogen bonded to Ser115 <ref name="Prom"/>. The purpose of the oxyanion hole is to stabilize the oxyanion that is formed after the nucleophilic attack of the transition state. Ser115 acts as a nucleophile, while His289 and Asp233 are coordinated to Ser115 to lower its pKa value so it can undergo catalytic activity<ref name="Prom"/>. The pKa of the nucleophile in the catalytic triad is lowered to allow the nucleophilic attack<ref name="Prom">Branneby, Cecilia. "Exploiting Enzyme Promiscuity for Rational Design." KTH Biotechnology (2005): Web. 10 Apr. 2013.</ref>. |
===Hydrophobic Groove === | ===Hydrophobic Groove === | ||
Line 30: | Line 30: | ||
==Medical Relevance== | ==Medical Relevance== | ||
- | PPT1 mutations and a decrease or depletion of PPT1 are the root cause of several diseases. Infantile neuronal ceroid lipofuscinosis (INCF) is characterized by impaired mental and motor development, including difficulty with walking, speaking, and intellectual function, beginning around the first or second year of life<ref name="PPT">PPT1. Genetics Home Reference. | + | PPT1 mutations and a decrease or depletion of PPT1 are the root cause of several diseases. Infantile neuronal ceroid lipofuscinosis (INCF) is characterized by impaired mental and motor development, including difficulty with walking, speaking, and intellectual function, beginning around the first or second year of life<ref name="PPT">"PPT1." Genetics Home Reference. N.p., Aug. 2013. Web. 10 Apr. 2014.</ref>. The PPT1 mutation involved in INCF replaces an arginine with a stop signal in the instructions to make the enzyme. This mutation leads to a vast reduction in the production of PPT1, which impairs the removal of fatty acids from proteins. This impaired removal leads to fatty acid accumulations throughout the body, particularly in neuronal cells in the brain<ref name="PPT"/>. Late-infantile neuronal ceroid lipofuscinosis has the same characteristics as INCF, but the mutation varies slightly. This leads to a slight reduction in the activity of PPT1 instead of completely wiping it out<ref name="PPT"/>. |
Mutations can also cause premature stop signals to be added to the instructions to create PPT1, resulting in Kufs disease<ref name="PPT"/>. This is characterized by seizures, problems with movement, and a decline of intellectual function, usually beginning in early adulthood<ref name="PPT"/>. Although premature stop signals are added, these mutations allow enough PPT1 to be produced so that the onset is later on in life and the life expectancy is higher. | Mutations can also cause premature stop signals to be added to the instructions to create PPT1, resulting in Kufs disease<ref name="PPT"/>. This is characterized by seizures, problems with movement, and a decline of intellectual function, usually beginning in early adulthood<ref name="PPT"/>. Although premature stop signals are added, these mutations allow enough PPT1 to be produced so that the onset is later on in life and the life expectancy is higher. |
Current revision
ββ
This Sandbox is Reserved from Jan 06, 2014, through Aug 22, 2014 for use by the Biochemistry II class at the Butler University at Indianapolis, IN USA taught by R. Jeremy Johnson. This reservation includes Sandbox Reserved 911 through Sandbox Reserved 922. |
To get started:
More help: Help:Editing |
Palmitoyl-Protein Thioesterase 1
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Palmitoyl Protein Thioesterase 1." UniProt. N.p., 1 Oct. 1996. Web. 10 Apr. 2014.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "PPT1." Genetics Home Reference. N.p., Aug. 2013. Web. 10 Apr. 2014.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Bellizzi JJ 3rd, Widom J, Kemp C, Lu JY, Das AK, Hofmann SL, Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4573-8. PMID:10781062 doi:10.1073/pnas.080508097
- ↑ 4.0 4.1 4.2 Branneby, Cecilia. "Exploiting Enzyme Promiscuity for Rational Design." KTH Biotechnology (2005): Web. 10 Apr. 2013.
External Resources
http://en.wikipedia.org/wiki/Palmitoyl_protein_thioesterase
https://www.counsyl.com/diseases/ppt1-related-neuronal-ceroid-lipofuscinosis/
http://en.wikipedia.org/wiki/Alpha/beta_hydrolase_fold
http://en.wikipedia.org/wiki/Catalytic_triad
http://www.biomedcentral.com/1471-2121/8/22
http://www.genecards.org/cgi-bin/carddisp.pl?gene=PPT1